Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
Haddad, Tufia C., D’Assoro, Antonino, Suman, Vera, Opyrchal, Mateusz, Peethambaram, Prema, Liu, Minetta C., Goetz, Matthew P., Ingle, James N.Мова:
english
Журнал:
Breast Cancer Research and Treatment
DOI:
10.1007/s10549-017-4616-7
Date:
December, 2017
Файл:
PDF, 832 KB
english, 2017
File converter
Більше результатів пошуку
More benefits 
